decreasing trends in overall opioid prescriptions in youth and the CDC guidelines may have had an impact on pediatric opioid prescribing practices in children, adolescents, and younger adults in the US from 2006 to 2018. JAMA Pediatr. Published online June 28, 2021. doi:10.1001/jamapediatrics.2021.1832


In Reply We read with interest the commentary from Cortellazzo Wiel et al and thank them for highlighting an important point regarding our research on opioid prescribing practices in youth. The authors comment on the importance of opioid prescribing in certain settings, while also emphasizing avoidance of opioids when alternative pain management options are present. We agree that opioid prescribing must be evidence based, with recognition that opioids are an appropriate treatment for children with specific conditions (particularly severe acute pain; certain chronic diseases, such as cancer; and palliative care), but that their use should be counterbalanced with an understanding of potential opioid-related risks, including adverse effects, intentional or unintentional overdose, and risk of future opioid use disorder.

In 2016, the US Centers for Disease Control and Prevention (CDC) released guidelines on opioid prescribing for chronic pain with a focus on adults. Subsequent research has demonstrated that these guidelines may have decreased opioid prescribing and certain high-risk prescribing practices in adults. Conversely, these guidelines may have had unintended consequences, such as leading clinicians to conduct rapid opioid tapers that have been associated with adverse outcomes, such as anxiety, depression, worsening of pain, and suicide. While the CDC guidelines may have had an impact on pediatric opioid prescribing— as shown in our study, which demonstrated decreasing trends in overall opioid prescriptions in youth and certain high-risk practices in adolescents—these guidelines were not intended for patients younger than 18 years. To ensure appropriate opioid prescribing for youth across all settings, national evidence-based pediatric- and adolescent-specific clinical practice guidelines are necessary to provide standardized clinician guidance for the treatment of both acute and chronic pain in this population. The publication of pediatric postoperative opioid prescribing guidelines earlier this year represents an important step in moving toward general opioid prescribing guidelines for youth.

Our study highlights current trends in opioid prescribing practices in young people based on age, with notable differences by age group for potential high-risk prescribing practices. While we were limited in determining the appropriateness of each opioid prescription in our study, our findings of increasing rates of high-dosage, long-duration, and extended-release or long-acting formulation prescriptions in young children warrant further study. Prescription opioids are implicated in a large percentage of opioid overdoses among youth, and opioids remain readily dispensed. Pediatric- and adolescent-specific opioid research and targeted interventions must be prioritized to prevent opioid-related morbidity and mortality within this population.

Madeline H. Renny, MD
Scott E. Hadland, MD, MPH, MS
Magdalena Cerdá, DrPH, MPH

Author Affiliations: Center for Opioid Epidemiology and Policy, Department of Population Health, New York University Grossman School of Medicine, New York (Renny, Cerdá); Division of Adolescent and Young Adult Medicine, Mass General Hospital for Children, Boston, Massachusetts (Hadland).

Corresponding Author: Madeline H. Renny, MD, Department of Population Health, New York University Grossman School of Medicine, 227 E 30th St, New York, NY 10016 (madeline.renny@nyulangone.org).


Conflict of Interest Disclosures: None reported.

CORRECTION

Error in Introduction: The Original Investigation titled “Effect of Whole-Genome Sequencing on the Clinical Management of Acutely Ill Infants With Suspected Genetic Disease: A Randomized Clinical Trial” was corrected to fix the first paragraph of the Introduction, which had incorrectly indicated that NICU costs were approximately $26 billion annually; the correct value is $17 billion, which reflects the cost of neonatal hospitalizations inclusive of those in the NICU. An irrelevant reference associated with the erroneous text was also removed.


Letters

jamapediatrics.com

© 2021 American Medical Association. All rights reserved.